Atezolizumab in the treatment of non-small cell lung cancer

01/2020

MUDr. Gyula Nyárs; doc. MUDr. David Vrána, Ph.D.

Komplexní onkologické centrum, nemocnice Nový Jičín

SUMMARY

Atezolizumab is a modified humanized IgG1 monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1). It is the one of few check-point inhibitors which can be used to treat patients with non-small cell lung cancer. Although it is currently registered in the Czech Republic only for the second and higher lines of palliative treatment after progression on chemotherapy or targeted therapy, unfortunately health insurance still does not reimburse it. The goal of this article is to summarize outcomes of the most important studies which proved the efficacy and safety of atezolizumab in the first and second line of palliative treatment.

Key words

PD-L1 inhibitor, non-small cell lung cancer, immunotherapy